State Street

State Street’s Research Team Announces Academic Partnership with Daniel Drezner of The Fletcher School, expanding Markets Research Capabilities in Arena of Geopolitical Risk

Retrieved on: 
Monday, April 8, 2024
Finance, Consulting, Professional Services, Public Policy, Government, Other Policy Issues, Department of the Treasury, Conference, Politics, University, The Washington Post, Data science, Tufts University, Foreign Affairs, Partnership, Risk, STT, Social media, Research, State Street Corporation, Publication, Language, Book, State Street, The Wall Street Journal, State

Mr. Drezner will partner with State Street Associates, the firm’s hub for partnerships with academics and fintech start-ups, which powers its award-winning markets research platform for foreign exchange trading, equities trading, and securities lending clients.

Key Points: 
  • Mr. Drezner will partner with State Street Associates, the firm’s hub for partnerships with academics and fintech start-ups, which powers its award-winning markets research platform for foreign exchange trading, equities trading, and securities lending clients.
  • “Our clients are increasingly contemplating the risk of ongoing and potential conflicts around the world as well as several high-stakes, national elections."
  • "I am honoured to collaborate with State Street Associates as its newest academic partner,” said Professor Drezner.
  • As part of his engagement with State Street, Professor Drezner will be a featured speaker at the 2024 Markets & Financing Research Conference.

Nkarta Announces Pricing of $240 Million Underwritten Offering

Retrieved on: 
Monday, March 25, 2024
Janus, SVB Securities, Montgomery Street, Mizuho Securities, 3rd Floor, Telephone, SAN, Research, Sale, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, Annual report, OrbiMed, Equity capital markets, NK, State Street

Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses.
  • The offering is expected to close on or about March 27, 2024, subject to customary closing conditions.
  • All securities in the offering are to be issued and sold by Nkarta.
  • The offering was made only by means of a prospectus supplement and accompanying prospectus describing the terms of the offering.

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

Retrieved on: 
Monday, March 25, 2024
SVB Securities, Telephone, Oppenheimer Holdings, Sale, Attention, Prospectus, Therapy, Nicollet Mall, State Street

WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share.

Key Points: 
  • WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share.
  • At closing, the aggregate gross proceeds of the offering to Aquestive, before deducting underwriting discounts and commissions and other offering expenses paid by Aquestive, were approximately $75.0 million.
  • Leerink Partners and Piper Sandler acted as joint bookrunning managers for the offering.
  • H.C. Wainwright & Co. and Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as financial advisors to the Company.

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

Retrieved on: 
Wednesday, March 20, 2024
SVB Securities, Epilepsy, Anaphylaxis, Telephone, Patient, Adrenaline, Ageing, Oppenheimer Holdings, Sale, Public expenditure, Attention, Prospectus, Therapy, Nicollet Mall, State Street

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share.

Key Points: 
  • WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share.
  • The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be approximately $75.0 million.
  • In addition, Aquestive has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about March 22, 2024, subject to satisfaction of customary closing conditions.

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, March 19, 2024
SVB Securities, Epilepsy, Anaphylaxis, Form, Telephone, Patient, Ageing, Adrenaline, Oppenheimer Holdings, Sale, Public expenditure, Attention, Security (finance), Prospectus, Therapy, Nicollet Mall, State Street, Pharmaceutical industry

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Key Points: 
  • WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
  • In addition, Aquestive expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.
  • All of the securities in the public offering are being offered by Aquestive.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Retrieved on: 
Tuesday, March 19, 2024
SVB Securities, BofA Securities, Madison Avenue, Form, Telephone, Patient, SAN, Sale, Attention, Cancer, Security (finance), Therapy, OrbiMed, Jefferies, IPSC, State Street, Jefferies Group

The offering includes participation from new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor.

Key Points: 
  • The offering includes participation from new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor.
  • The gross proceeds from the underwritten offering and private placement are expected to be approximately $100.0 million before deducting underwriting discounts and commissions and other offering expenses.
  • BofA Securities, Jefferies, and Leerink Partners are acting as the joint bookrunning managers for the underwritten offering.
  • A final prospectus supplement relating to and describing the terms of the underwritten offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov.

Presto Automation Announces Pricing of $1.2M Registered Direct Offering Priced above Nasdaq Minimum Price

Retrieved on: 
Thursday, March 14, 2024
Form, SAN, Presto, Sale, Security (finance), Suite, State Street, S-3, Cryptocurrency

The offering is expected to close on or about March 18, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close on or about March 18, 2024, subject to the satisfaction of customary closing conditions.
  • Chardan is acting as sole placement agent for the offering.
  • The gross proceeds to Presto from this offering are expected to be approximately $1.2 million, before deducting Chardan’s fees and other offering expenses payable by Presto.
  • Presto intends to use the net proceeds from this offering for working capital and general corporate purposes.

Scorpius Holdings, Inc. Announces Closing of Public Offering

Retrieved on: 
Tuesday, March 12, 2024
Prospectus, CDMO, State Street, ThinkEquity, Sale, Attention, Life insurance

DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for gross proceeds of $1,500,000, before deducting underwriting discounts and offering expenses.

Key Points: 
  • DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for gross proceeds of $1,500,000, before deducting underwriting discounts and offering expenses.
  • The Company intends to use the proceeds from the offering for working capital and general corporate purposes.
  • ThinkEquity acted as sole book-running manager for the offering.
  • Copies of the final prospectus supplement and the accompanying base prospectus relating to the offering may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004, Attention: Prospectus Department.

HarborOne Bancorp, Inc. Names Stephen W. Finocchio as Executive Vice President and Chief Financial Officer

Retrieved on: 
Thursday, March 28, 2024
Finance, Banking, Accounting, Professional Services, Legal, Fennel, Aswath Damodaran, Business, Strategic planning, Capital, University, State Street Corporation, Senior, Consultant, Multimedia, Treasury, State Street, Management

HarborOne Bancorp, Inc. today announced the appointment of Stephen W. Finocchio as Executive Vice President and Chief Financial Officer, HarborOne Bancorp, Inc. and HarborOne Bank.

Key Points: 
  • HarborOne Bancorp, Inc. today announced the appointment of Stephen W. Finocchio as Executive Vice President and Chief Financial Officer, HarborOne Bancorp, Inc. and HarborOne Bank.
  • Finocchio will oversee all Finance areas, including Accounting, Reporting, Treasury, and Investor Relations.
  • “Stephen’s deep experience in driving growth and innovation in large financial institutions brings a new perspective and skill set in helping HarborOne meet its growth aspirations,” said Joseph F. Casey, President and CEO of HarborOne Bancorp, Inc. and HarborOne Bank.
  • Earlier in his career, he served as Managing Director - Structured Finance for State Street Global Markets, LLC from 1995 to 2010.

Boundless Bio Announces Pricing of Initial Public Offering

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Genetics, Clinical Trials, Other Health, SVB Securities, Floor, Madison Avenue, Goldman Sachs, A-DNA, Telephone, Patient, DNA, Sale, Attention, Guggenheim, Security (finance), Biology, Guggenheim Partners, Prospectus, Nicollet Mall, State Street

Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share.

Key Points: 
  • Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share.
  • All of the shares are being offered by Boundless Bio.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $100.0 million.
  • In addition, Boundless Bio has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.